Exelixis, Inc. has reported strong financial results for the third quarter of 2026, showcasing significant growth in its cabozantinib franchise. The results, released on October 29, 2026, are crucial for the company as they reflect its ongoing success in the competitive biological products industry.

Exelixis, Inc. operates in the biological products sector (SIC 2836) and is listed on the Nasdaq under the ticker EXEL. The company is known for its focus on developing and commercializing innovative medicines for cancer patients. Its recent filings include various 8-K forms and a Schedule 13D/A, indicating active corporate governance and strategic developments.

The SEC filing reveals that Exelixis reported total revenues of $658.7 million for the quarter ending September 30, 2026. This figure marks an increase from $597.8 million during the same period in 2025. Notably, net product revenues from the cabozantinib franchise reached $604.9 million, up from $542.9 million in the prior year. The growth in revenue is attributed to increased sales volume and a rise in average net selling price.

Additionally, collaboration revenues were reported at $53.8 million, slightly down from $54.8 million year-over-year. This decrease is primarily due to lower milestone-related revenues and development cost reimbursements, although it was partially offset by higher royalty revenues from cabozantinib sales outside the U.S. generated by Exelixis' collaboration partner, Ipsen Pharma SAS.

Exelixis' President and CEO, Michael M. Morrissey, Ph.D., emphasized the company's strategic focus during the quarter. He stated, "Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity." Morrissey highlighted the momentum gained in the zanzalintinib development program, which is set to advance through trial initiations and enrollment progress.

The filing indicates that Exelixis remains committed to disciplined capital deployment, investing in its research and development portfolio while also returning value to shareholders through its stock repurchase program. The company is actively evaluating external innovation opportunities to strengthen its pipeline and create long-term value for patients and stakeholders.

Looking ahead, Exelixis is expected to continue focusing on its key corporate objectives and milestones in both commercial and clinical development. The filing does not specify what happens next, but the company has scheduled a conference call and webcast to discuss these results further.

In summary, Exelixis, Inc.'s strong financial results for Q3 2026 reflect its successful execution in the biological products sector, particularly with its cabozantinib franchise. The company’s strategic focus on pipeline development and shareholder value positions it well for future growth.